tocilizumab - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.02 [0.62, 1.68]< 10%1 study (1/-)47.2 %some concernnot evaluable moderatecrucial-
deaths 0.90 [0.75, 1.09]< 121%9 studies (9/-)86.1 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.16 [0.73, 1.84]< 10%1 study (1/-)26.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.76 [0.56, 1.05]< 116%5 studies (5/-)95.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.26 [1.04, 1.52]> 136%5 studies (5/-)99.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.81 [0.66, 1.01]< 118%5 studies (5/-)97.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.16 [0.90, 1.49]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.82 [0.54, 1.25]< 10%3 studies (3/-)82.6 %some concernnot evaluable moderateimportant-
ICU admission 0.80 [0.29, 2.16]< 177%2 studies (2/-)67.1 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.84 [0.59, 1.21]< 10%3 studies (3/-)82.4 %some concernnot evaluable moderateimportant-
adverse events 1.99 [0.68, 5.79]< 184%3 studies (3/-)10.3 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.